CLDX – celldex therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Celldex Therapeutics to Present at Upcoming Investor Conferences
Form 4 Celldex Therapeutics, For: Nov 18 Filed by: MARINO JAMES J
Form SC 13G/A Celldex Therapeutics, Filed by: Point72 Asset Management, L.P.
Form SC 13G/A Celldex Therapeutics, Filed by: EVENTIDE ASSET MANAGEMENT, LLC
Form SC 13G/A Celldex Therapeutics, Filed by: RTW INVESTMENTS, LP
Form SC 13G/A Celldex Therapeutics, Filed by: Polar Capital Holdings Plc
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.